Search

Your search keyword '"Jesús"' showing total 2,769 results

Search Constraints

Start Over You searched for: Author "Jesús" Remove constraint Author: "Jesús" Journal blood Remove constraint Journal: blood
2,769 results on '"Jesús"'

Search Results

1. ADAMTS13 recovery in acute thrombotic thrombocytopenic purpura after caplacizumab therapy

2. Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

3. Molecular taxonomy of myelodysplastic syndromes and its clinical implications

4. Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma

7. Novel variants in GALE cause syndromic macrothrombocytopenia by disrupting glycosylation and thrombopoiesis

8. Acute promyelocytic leukemia: long-term outcomes from the HARMONY project

11. Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents

12. Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome–negative adult lymphoblastic leukemia

13. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma

15. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

17. Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma

18. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA

19. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE

20. Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma

21. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma

22. Immunodeficiency and bone marrow failure with mosaic and germline TLR8 gain of function

23. Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set

24. Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma

25. Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes

26. Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma

28. Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

32. CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1− mantle cell lymphoma

33. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma

34. Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients

35. Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM

36. Mutually-Exclusive Pathways between IKZF1 plus and RAS Mutations and TP53 double-Hit Alterations Lead Relapse in B-Other, Ph-like and Hyperdiploidy Genetic Groups in Adult B-Cell Acute Lymphoblastic Leukemia

37. TRAF3-Inactivated Chronic Lymphocytic Leukemia Cells Show an Enhanced Metabolic Plasticity That Can be Attenuated By Glutaminolysis and Mitochondrial Pyruvate Import Inhibition

38. Graft-Versus-Host Disease (GvHD) and Steroid-Refractory GvHD after Allogeneic Hematopoietic Stem Cell Transplantation: A Large Real-World EBMT-Based Epidemiology and Treatment Pattern Study

39. T-cell defects in patients with ARPC1B germline mutations account for combined immunodeficiency

40. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

41. The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia

45. Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Is an Independent Prognostic Factor for Multiple Myeloma and Could Complement Prognosis Value of Minimal Residual Disease

46. Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients

48. Immune Biomarkers of Survival and Severe Infection in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with the Backbone Regimen Lenalidomide and Dexamethasone (Rd)

49. Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML - Results of the European Harmony Alliance

50. Rearrangements Involving 11q23/KMT2A: Mutational Landscape and Prognostic Implications - Results of the Harmony Alliance AML Database

Catalog

Books, media, physical & digital resources